Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-23-057310
Filing Date
2023-03-02
Accepted
2023-03-02 07:57:35
Documents
5
Effectiveness Date
2023-03-02

Document Format Files

Seq Description Document Type Size
1 S-8 d472327ds8.htm S-8 49989
2 EX-5.1 d472327dex51.htm EX-5.1 8415
3 EX-23.1 d472327dex231.htm EX-23.1 1418
4 EX-FILING FEES d472327dexfilingfees.htm EX-FILING FEES 20650
5 GRAPHIC g472327dsp7.jpg GRAPHIC 6180
  Complete submission text file 0001193125-23-057310.txt   90136
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-270208 | Film No.: 23696463
SIC: 2834 Pharmaceutical Preparations